COA ↓

Product

COA Doc

SYN-2633

99.0% Purity SYN-2633 Research Grade HPLC Verified

AOD-9604

hGH[176-191] Lipolytic Fragment · Research Grade

Select Strength — 5mg

$115.00

C₇₈H₁₂₃N₂₃O₂₃S₂ MW: 1817.07 g/mol CAS: 221231-10-3

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

HPLC Purity

Lot Number SYN-2633-AOD

Test Date

Labeled 99.0%

Actual 99.0%

HPLC Purity

Lot Number SYN-2532-AOD

Test Date

Labeled 99.0%

Actual 99.3%

Research Data

KEY FINDINGS

🧬

GRAS

FDA GRAS Status

AOD-9604 holds FDA Generally Recognised As Safe designation — evaluated in Phase IIb obesity trials

🔬

IGF-1 Elevation

No IGF-1 elevation — lipolytic activity without anabolic or diabetogenic GH effects

✅

99.0%

HPLC-Verified Purity

Current batch SYN-2633, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔥 Selective Lipolysis

hGH[176-191] — Fat Loss Without Growth or Insulin Effects

Heffernan et al. characterised AOD-9604's selective lipolytic mechanism, confirming 17% fat mass reduction equivalent to full-length GH in obese mouse models — with zero IGF-1 elevation, zero insulin resistance, and no anabolic tissue growth effects at all tested doses.

🔬 17% fat mass reduction with zero IGF-1 elevation — the lipolytic activity of GH isolated from its anabolic and diabetogenic effects.

PMID 11397794 — Endocrinology

0 IGF-1

GH Lipolytic Activity Without Anabolic or Diabetogenic Effects

AOD-9604 is the C-terminal fragment of human growth hormone (hGH[176-191]) that replicates GH's fat-burning activity via beta-3 adrenergic receptor stimulation — without triggering IGF-1 elevation, insulin resistance, or anabolic effects associated with full-length GH.

Lipid Metabolism — AOD-9604 vs. Full-Length hGH

Fat mass reduction (AOD-9604) −17%

IGF-1 change (AOD-9604) 0%

Insulin sensitivity change 0%

Source: Heffernan M et al., Endocrinology, 2001

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2633-AOD

Specification	Value
CAS Number	221231-10-3
Molecular Formula	C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight	1817.07 g/mol
Purity (HPLC)	99.0%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

17 %

Fat Mass Reduction with Zero IGF-1 Elevation or Insulin Resistance

Fat mass (AOD-9604) −17%

IGF-1 change (AOD-9604) 0%

Fat mass (Full hGH) −15%

Comparative Activity Profile

AOD-9604 Full hGH

Observed Adverse Indicators

10%

Injection-site erythema

low

Transient headache

low

IGF-1 elevation

low

Insulin resistance / glucose effect

low

⚠️ Theoretical Concern

FDA GRAS & Phase IIb Safety Context

AOD-9604 is the only growth hormone fragment with FDA GRAS designation, based on Phase IIb obesity trial safety data evaluated at doses up to 1mg/day over 24 weeks.

FDA GRAS designation — evaluated in Phase IIb human obesity trials at 500µg–1mg/day over 24 weeks
Zero IGF-1 elevation confirmed — does not activate GH receptor anabolic signalling pathway
No insulin resistance or diabetogenic effects at any studied dose
For in vitro laboratory research use only — not for human or veterinary administration

Peer-Reviewed Literature

RESEARCH CITATIONS

Endocrinology

The Antiobesity Effects of AOD-9604 (hGH[176-191]) — Selective Lipolytic Activity

2001 Heffernan M et al.

PMID 11397794 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.